Jaguar Health unit Napo sponsors pediatric intestinal failure panel as crofelemer studies continue
Bitget2026/10/06 13:00Jaguar Health’s Napo unit outlined progress in studies of oral crofelemer for pediatric intestinal failure tied to MVID or SBS-IF. Results were already presented in June 2026 at an ESPGHAN meeting from ongoing investigational use in children treated for over a year. Studies showed meaningful reductions in dependence on parenteral support, without notable clinical or laboratory safety concerns. Program timeline points to a planned mid-2027 NDA filing for crofelemer in MVID, a rare intestinal failure disease. Napo will sponsor an intestinal failure panel on Oct. 30, 2026 at a pediatric gastroenterology meeting in Abu Dhabi. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610060900ACCESSWRNAPR_____1232993) on October 06, 2026, and is solely responsible for the information contained therein.
- Jaguar Health’s Napo unit outlined progress in studies of oral crofelemer for pediatric intestinal failure tied to MVID or SBS-IF.
- Results were already presented in June 2026 at an ESPGHAN meeting from ongoing investigational use in children treated for over a year.
- Studies showed meaningful reductions in dependence on parenteral support, without notable clinical or laboratory safety concerns.
- Program timeline points to a planned mid-2027 NDA filing for crofelemer in MVID, a rare intestinal failure disease.
- Napo will sponsor an intestinal failure panel on Oct. 30, 2026 at a pediatric gastroenterology meeting in Abu Dhabi.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
